Filtered By:
Drug: Gilenya

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 88 results found since Jan 2013.

Fingolimod Reduces Hemorrhagic Transformation Associated With Delayed Tissue Plasminogen Activator Treatment in a Mouse Thromboembolic Model Basic Sciences
Conclusion— This study confirms the protective efficacy of fingolimod as a treatment against ischemic stroke in another rodent model of stroke (thromboembolic occlusion), and suggests that fingolimod could potentially be used in combination with tPA to reduce the risk of brain hemorrhage.
Source: Stroke - January 18, 2013 Category: Neurology Authors: Campos, F., Qin, T., Castillo, J., Seo, J. H., Arai, K., Lo, E. H., Waeber, C. Tags: Acute Cerebral Infarction, Embolic stroke, Emergency treatment of Stroke, Thrombolysis, Other Stroke Treatment - Medical Basic Sciences Source Type: research

Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke
This article is part of a Special Issue entitled: Neuro inflammation: A common denominator for stroke, multiple sclerosis and Alzheimer's disease
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - October 25, 2015 Category: Molecular Biology Source Type: research

Combination of an Immune Modulator Fingolimod with Alteplase in Acute Ischemic Stroke: A Pilot Trial.
CONCLUSIONS: -In this pilot study, combination therapy of fingolimod and alteplase was well tolerated, attenuated reperfusion injury and improved clinical outcomes in AIS patients. These findings need to be tested in further clinical trials. Clinical Trial Registration Information-www.clinicaltrials.gov. Identifier: NCT02002390. PMID: 26202811 [PubMed - as supplied by publisher]
Source: Circulation - July 22, 2015 Category: Cardiology Authors: Zhu Z, Fu Y, Tian D, Sun N, Han W, Chang G, Dong Y, Xu X, Liu Q, Huang D, Shi FD Tags: Circulation Source Type: research

Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation
Publication date: Available online 11 May 2016 Source:The Lancet Neurology Author(s): Ángel Chamorro, Ulrich Dirnagl, Xabier Urra, Anna M Planas Treatments for acute ischaemic stroke continue to evolve after the superior value of endovascular thrombectomy was confirmed over systemic thrombolysis. Unfortunately, numerous neuroprotective drugs have failed to show benefit in the treatment of acute ischaemic stroke, making the search for new treatments imperative. Increased awareness of the relevance of rigorous preclinical testing, and appropriate selection of study participants, might overcome the barriers to progress...
Source: The Lancet Neurology - May 11, 2016 Category: Neurology Source Type: research

Fingolimod (FTY720) reduces cortical infarction and neurological deficits during ischemic stroke through potential maintenance of microvascular patency.
Abstract Fingolimod (FTY720) a functional sphingosine-1-phosphate receptor 1 (S1P1) antagonist reduces infarct volume and improves neurological deficits in different rodent stroke models by modulating inflammatory and immune processes. However, studies on FTY720 regarding its non-immunological efficacy on ischemic cerebral tissue are sparse. Here we investigated whether FTY720 has cytoprotective and restorative properties following ischemic stroke in mice. Male C57Bl/6 mice received FTY720 (1mg/kg) or a vehicle solution intraperitoneally immediately prior to transient middle cerebral artery occlusion (tMCAO; 30 mi...
Source: Current Neurovascular Research - August 22, 2016 Category: Neurology Authors: Fluri F, Schuhmann MK, Krstić M, Kleinschnitz C Tags: Curr Neurovasc Res Source Type: research

Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities
This study used a rigorous study design in normal male C57BL/6JOlaHsd mice and in mice with common stroke comorbidities to further evaluate the translational potential of fingolimod. Stroke was induced via middle cerebral artery electrocoagulation in 8–9-week old mice (young mice), 18 month old mice (aged mice), and in high-fat diet-fed 22-week old ApoE−/− mice (hyperlipidaemic mice). Recovery was evaluated using motor behavioural tests 3 and 7 days after stroke. Tissue damage was evaluated at 7 days. A lower dose of fingolimod, 0.5 mg/kg, but not 1 mg/kg, increased lesion size but decreased ipsilateral brain at...
Source: Frontiers in Pharmacology - July 13, 2022 Category: Drugs & Pharmacology Source Type: research

Selective Sphingosine 1-Phosphate Receptor 1 Agonist Is Protective Against Ischemia/Reperfusion in Mice Brief Report
Conclusions—The selective S1P1 agonist LASW1238 reduces infarct volume after ischemia/reperfusion in mice, but only when lymphopenia is sustained for at least 24 hours. S1P1 and lymphocytes are potential targets for drug treatment in stroke. Defining the best drug dosing regimens to control the extent and duration of lymphopenia is critical to achieve the desired effects.
Source: Stroke - November 27, 2016 Category: Neurology Authors: Vanessa H. Brait, Gema Tarrason, Amadeu Gavalda, Nuria Godessart, Anna M. Planas Tags: Basic Science Research, Inflammation, Ischemia Brief Reports Source Type: research

The emerging role of FTY720 as a sphingosine 1 ‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms
Three important mechanisms for neuroprotective effects of FTY720 have been described. Functional antagonistic, functional agonistic and receptor-independent mechanisms. Here, we review these mechanisms in more details and describe animal model and in clinical trial studies AbstractFinding novel and effective drugs for the treatment of ischemic stroke is warranted because there is not a definitive treatment for this prevalent disease. Due to the relevance between the sphingosine 1-phosphate (S1P) receptor and several neurological diseases including ischemic stroke, it seems that fingolimod (FTY720), as an agonist of S1P rec...
Source: Brain and Behavior - May 10, 2021 Category: Neurology Authors: Maryam Naseh, Jafar Vatanparast, Ali Rafati, Mahnaz Bayat, Masoud Haghani Tags: REVIEW Source Type: research

The efficacy and safety of fingolimod plus standardized treatment versus standardized treatment alone for acute ischemic stroke: A systematic review and meta ‐analysis
This study was conducted according to the PRISMA (Preferred Reporting Items for Systemic review and Meta-Analysis) statement. We searched for publications on the PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical trials, CNKI, Wanfang Data, VIP, CBM up to August 2021. We compiled five studies; a main meta-analysis forest plots were conducted for the values of the proportion of patients whose modified Rankin scale (MRS) score was 0 –1 at day 90. There were heterogeneities in each study; the method of sensitivity analysis was performed. A sensitivity analysis was performed with a mean difference (MD) ...
Source: Pharmacology Research and Perspectives - May 19, 2022 Category: Drugs & Pharmacology Authors: Peng Bai, Runxiu Zhu, Ping Wang, Feng Jiang, Jin Zhen, Yuan Yao, Chenhui Zhao, Zihong Liang, Meiling Wang, Bin Liu, Min Li, Na Li, Jun Yuan Tags: ORIGINAL ARTICLE Source Type: research

Clinical Trials of Immunomodulation in Ischemic Stroke
Abstract Inflammatory mechanisms are currently considered as a prime target for stroke therapy. There is evidence from animal studies that immune signals and mediators can have both detrimental and beneficial effects in particular stages of the disease process. Moreover, several of these mechanisms are turned on with sufficient delay after ischemia onset to make them amenable to therapeutic intervention. Several clinical proof-of concept trials have investigated the efficacy of different immunomodulatory approaches in patients with stroke. Trials targeting the innate immune system have focused on reduction of micr...
Source: Neurotherapeutics - July 12, 2016 Category: Neurology Source Type: research

Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow
ObjectiveThe present study was undertaken to determine the efficacy of coadministration of fingolimod with alteplase in acute ischemic stroke patients in a delayed time window.MethodsThis was a prospective, randomized, open ‐label, blinded endpoint clinical trial, enrolling patients with internal carotid artery or middle cerebral artery proximal occlusion within 4.5 to 6 hours from symptom onset. Patients were randomly assigned to receive alteplase alone or alteplase with fingolimod. All patients underwent pretreatme nt and 24‐hour noncontrast computed tomography (CT)/perfusion CT/CT angiography. The coprimary endpoint...
Source: Annals of Neurology - November 2, 2018 Category: Neurology Authors: De ‐Cai Tian, Kaibin Shi, Zilong Zhu, Jia Yao, Xiaoxia Yang, Lei Su, Sheng Zhang, Meixia Zhang, Rayna J. Gonzales, Qiang Liu, DeRen Huang, Michael F. Waters, Kevin N. Sheth, Andrew F. Ducruet, Ying Fu, Min Lou, Fu‐Dong Shi Tags: Research Article Source Type: research

Selective Sphingosine-1-Phosphate Receptor 1 Modulation Attenuates Experimental Intracerebral Hemorrhage Basic Sciences
Conclusions— S1PR1 modulation via RP101075 provides protection in experimental ICH. Together with the advantageous pharmacological features of RP101075, these results warrant further investigations of its mechanisms of action and translational values in ICH patients.
Source: Stroke - June 26, 2016 Category: Neurology Authors: Sun, N., Shen, Y., Han, W., Shi, K., Wood, K., Fu, Y., Hao, J., Liu, Q., Sheth, K. N., Huang, D., Shi, F.-D. Tags: Intracranial Hemorrhage Basic Sciences Source Type: research